Evidence map›Paper›PMID 33807411›Full record

ArticleCancers2021

Covalent Cysteine Targeting of Bruton's Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells.

Emilie Logie, Chandra S Chirumamilla, Claudina Perez-Novo, Priyanka Shaw, Ken Declerck, Ajay Palagani, Savithri Rangarajan, Bart Cuypers, Nicolas De Neuter, Fazil Mobashar Hussain Urf Turabe and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Emilie LogieLaboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, Campus Drie Eiken, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0003-1053-2409
Chandra S ChirumamillaLaboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, Campus Drie Eiken, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Claudina Perez-NovoLaboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, Campus Drie Eiken, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0003-4562-4346
Priyanka ShawPlasma Lab for Applications in Sustainability and Medicine Antwerp (PLASMANT), Department of Chemistry, University of Antwerp, 2610 Wilrijk, Belgium.ORCID 0000-0002-8682-1592
Ken DeclerckLaboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, Campus Drie Eiken, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Ajay PalaganiLaboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, Campus Drie Eiken, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Savithri RangarajanPamGene International B.V., 5211 Hertogenbosch, The Netherlands.ORCID 0000-0003-2586-8992
Bart CuypersBiomedical Informatics Network Antwerp (Biomina), Department of Informatics, University of Antwerp, 2610 Wilrijk, Belgium.
Nicolas De NeuterBiomedical Informatics Network Antwerp (Biomina), Department of Informatics, University of Antwerp, 2610 Wilrijk, Belgium.
Fazil Mobashar Hussain Urf TurabeLymphocyte Signaling Research Laboratory, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 1308232, Singapore.
Navin Kumar VermaLymphocyte Signaling Research Laboratory, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 1308232, Singapore.ORCID 0000-0002-5940-6633
Annemie BogaertsPlasma Lab for Applications in Sustainability and Medicine Antwerp (PLASMANT), Department of Chemistry, University of Antwerp, 2610 Wilrijk, Belgium.ORCID 0000-0001-9875-6460
Kris LaukensBiomedical Informatics Network Antwerp (Biomina), Department of Informatics, University of Antwerp, 2610 Wilrijk, Belgium.ORCID 0000-0002-8217-2564
Fritz OffnerHematology, Department of Internal Medicine, Ghent University, 9000 Ghent, Belgium.
Pieter Van VlierbergheDepartment of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0001-9063-7205
Xaveer Van OstadeLaboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, Campus Drie Eiken, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Wim Vanden BergheLaboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, Campus Drie Eiken, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0003-0161-7355
University of Antwerp · BEGhent University · BENanyang Technological University · SGPamGene (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a hematological malignancy characterized by plasma cells' uncontrolled growth. The major barrier in treating MM is the occurrence of primary and acquired therapy resistance to anticancer drugs

Indexed as

BTKglucocorticoidsibrutinibmultiple myelomatherapy resistancewithaferin A

Identifiers

PMID33807411
PMCPMC8037275
OpenAlexW3148093790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.